Woebot Health
14
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
28.6%
4 terminated/withdrawn out of 14 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
80%
8 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]
Role: lead
Potency and Precision Investigation
Role: lead
Participant Satisfaction With the BUILD Mobile Application
Role: lead
The Anchor Study: Digitally Delivered Intervention for Reducing Problematic Substance Use
Role: lead
Feasibility and Acceptability of W-GenZD vs CBT-light Teletherapy for Adolescents Seeking Mental Health Services
Role: lead
W-PPMA for Postpartum Mothers
Role: lead
Pilot: Digital Therapeutic vs Education for the Management of Problematic Substance Use
Role: lead
A Six-Month Prospective Follow-Up Study of WB001
Role: lead
How Phenotypical Characteristics of Woebot Users Are Related to Clinical Outcomes
Role: lead
W-SUDs for COVID-19
Role: lead
Digital Therapeutic vs Educational App for Depression Among Adolescents
Role: lead
Pivotal Test: WB001
Role: lead
Woebot for Substance Use Disorders
Role: lead
Digital Therapeutic vs Psychoeducation for Management of Mild to Moderate Depression in Adolescents
Role: lead
All 14 trials loaded